Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome (Q43716462)

26 November 2017

title

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome (English)

1 reference

26 November 2017

Chen Wang

1 reference

26 November 2017

Shaobo Chen

series ordinal

1 reference

26 November 2017

Bing Feng

series ordinal

1 reference

26 November 2017

Yuzhou Guan

series ordinal

1 reference

26 November 2017

publication date

27 January 2014

1 reference

26 November 2017

1 reference

26 November 2017

1 reference

26 November 2017

1 reference

26 November 2017

page(s)

325-328

1 reference

Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome

26 November 2017

cites work

1 reference

Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders

21 January 2018

1 reference

Treatment in Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line

21 January 2018

1 reference

Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.

21 January 2018

1 reference

Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.

21 January 2018

1 reference

Proteasome inhibitor, bortezomib, for myeloma and lymphoma

21 January 2018

1 reference

The proteasome--an emerging therapeutic target in cancer

21 January 2018

1 reference

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

21 January 2018

1 reference

Humoral immunity due to long-lived plasma cells.

21 January 2018

1 reference

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

21 January 2018

1 reference

Long-lasting treatment effect of rituximab in MuSK myasthenia.

21 January 2018

1 reference

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

21 January 2018

1 reference

Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

21 January 2018

1 reference

Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis

21 January 2018

1 reference

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

21 January 2018

1 reference

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

21 January 2018

1 reference

Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.

21 January 2018

1 reference

ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

Death, destruction, and the proteasome

21 January 2018

1 reference

Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro

21 January 2018

1 reference

Caspase activation inhibits proteasome function during apoptosis

21 January 2018

1 reference

Proteasome inhibitors in lung cancer

21 January 2018

1 reference

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MUS.24122

1 reference

26 November 2017

1 reference